First Generic of HIV-1 Antiretroviral Atazanavir Launches in the U.S.

Brand-name Reyataz (Bristol-Myers Squibb) generated annual sales of more than $400 million in 2017

Teva Pharmaceutical Industries Ltd. has launched the first generic version of Reyataz (atazanavir, Bristol-Myers Squibb) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection for patients 6 years of age and older weighing at least 15 kg.

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.

Source: Teva; December 27, 2017.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to or online at